63 results about "Protein S" patented technology

The invention discloses a novel coronavirus pneumonia (COVID-19) serological diagnosis kit. The kit comprises an S-IgM / IgG test strip and an N-IgM / IgG test strip, the double-antigen quadruple detection kit can be used for simultaneously detecting four indexes of an IgM / IgG antibody for resisting novel coronavirus spinous process protein S and an IgM / IgG antibody for resisting novel coronavirus nucleocapsid protein N in serum of a patient suffering from novel coronavirus pneumonia COVID-19. According to the kit, the detection sensitivity is improved through quantum dot fluorescence labeling andmultistage coupling amplification signals, the detection accuracy is improved through double-antigen quadruple detection, and the biological safety in the detection process is guaranteed by establishing a virus inactivation system. The kit is suitable for whole blood, plasma and serum detection, and can be applied to novel COVID-19 serological diagnosis.

The invention discloses a fusion protein of a novel coronavirus envelope protein and an application of the fusion protein. The fusion protein (SARS2-RBD-Fc) is obtained by fusing an RBD structural domain of a novel coronavirus envelope protein S with an antibody Fc fragment; and as a subunit vaccine, the fusion protein can induce an organism to generate an efficient neutralizing antibody through nasal drip immunization and intramuscular injection. It indicates that the SARS2-RBD-Fc can be used as a candidate vaccine for preventing and treating new coronavirus infection.

The present invention relates to methods for the identification of compounds that increase or decrease the inhibitory effect of TFPI on tissue factor activity and / or Factor Xa activity and / or thrombin formation. The invention also relates to methods for the identification of compounds that increase or decrease the co-factor activity of Protein S in TFPI-mediated inhibition of tissue factor and / or Factor Xa activity. This invention also relates to a pharmaceutical composition comprising the compounds identifiable by such methods. The invention also relates to methods for the regulation of tissue factor activity by influencing the interaction between Protein S and Tissue Factor Pathway Inhibitor.

A yolk antibody for SARS coronavirus is prepared through injecting the antigen, which may be recombinant genetic protein S, M, or E,or the antigen epitope for said protein able to represent SARS coronavirus, or the synthetic polypeptide of said protein, etc, in health hen for primary immunizing, booster immunizing, collecting its egg, extracting yolk, and extracting the yolk antibody from it. It can also be prepared to become liquid preparation. It can be used to prevent SARS.

The present invention relates to the use of a matured, glycosylated Spike (S) protein of SARS Coronavirus, fragments of the S protein, methods for producing the same, their use in detecting SARS infection, and their use or the use of their corresponding antibodies to treat patients suffering from SARS.

The present invention provides methods for treating subjects having or at risk of having a neuropathological disorder or brain inflammatory diseases with and without vascular involvement, and systemic inflammatory vascular disease by administering a therapeutically effective amount of Activated Protein C (APC) to the subject. Brain disorders and brain inflammatory vascular diseases that can be treated by the invention method include all neurodegenerative diseases with different types of neuronal dysfunction, including stroke, Alzheimer's disease, Parkinson's disease, Huntington disease, neuroimmunological disorders such as multiple scelrosis and Gullian-Barre, encephalitis, meningitis, as well as other peripheral vascular diseases, such as diabetes, hypertension, artheriosclerosis. Also included are methods of treatment using APC in combination with a co-factor, such as Protein S.

The invention discloses a vesicular stomatitis virus vector-based novel coronavirus chimeric recombinant vaccine as well as a preparation method and application thereof. The active component of the recombinant vaccine is recombinant virus rVSV-SARS-CoV / 2-RBD, and is a virus obtained by replacing glycoprotein G of the vesicular stomatitis virus with chimeric envelope protein S; the chimeric envelope protein S is a protein obtained by replacing the RBD of the SARS-CoV envelope protein S with the RBD of the SARS-CoV-2 envelope protein S; the amino acid sequence of the RBD of the SARS-CoV envelopeprotein S is the 315-536 site of the amino acid sequence of the SARS-CoV envelope protein S; and the amino acid sequence of the RBD of the SARS-CoV-2 envelope protein S is the 319-541 site of the amino acid sequence of the SARS-CoV-2 envelope protein S. The recombinant virus has great significance to vaccine development of new coronaviruses.

The invention discloses a stable coronavirus recombinant protein dimer and an expression vector thereof. Coronavirus recombinant protein is composed of coronavirus S protein S-RBD, coronavirus N protein CTD region N-CTD and a linker for coupling the coronavirus S protein S-RBD and the coronavirus N protein CTD region N-CTD. The coronavirus recombinant protein in some embodiments can form and maintain a stable dimer structure, avoids monomer S-RBD degradation, is beneficial to improving the immunogenicity of the coronavirus recombinant protein, and is expected to be used for preparing detectionreagent raw materials, vaccines, antibodies and preventive or therapeutic drugs. The coronavirus recombinant protein dimers in some embodiments have good immunogenicity and have wide application prospects in the vaccine development field. Expression vectors in some embodiments can easily express the coronavirus recombinant protein dimers and have high expression quantity.

The invention provides vectors containing a multiple cloning site comprising a PrS tag or a PrS2 tag from Myxococcus xanthus. Methods are provided for enhancing solubility of a target protein using Protein S tagged target fusion proteins.

The invention relates generally to a new functional protein S assay and kit that is based on the ability of endogenous protein S to prolong clotting time. In the assay procedure, a test plasma sample is diluted with protein S deficient plasma, followed by the addition of purified or recombinant tissue factor (pTF or rTF), purified natural or synthetic phospholipid (pPL or sPL) and activated protein C (APC) or protein C activator (PCA). The clotting time is then measured and compared to a standard curve or a normal control.

The invention discloses a polypeptide enzyme-linked immunosorbent assay kit for detecting a novel coronavirus surface spinous process protein S unique specific antibody. The kit comprises an elisa plate coated with SARS-CoV2 surface spinous process protein S unique specificity dominant linear B cell antigen polypeptide, a sample diluent, negative control serum, positive control serum, a horse radish peroxidase labeled antibody, a concentrated washing solution, an enzyme substrate solution and a stop solution. The kit disclosed by the invention is high in specificity and good in repeatability,can be simply and conveniently used for detecting the novel coronavirus unique antibody, reduces false positive, can be used for large-scale serological detection and epidemiological investigation, and evaluates the infection condition of the novel coronavirus.

Protein S is a significant neuroprotectant when administered after focal ischemic stroke and prevents hypoxic / re-oxygenation injury. Purified human plasma-derived or recombinant protein S improves motor neurological function after stroke, and reduced brain infarction and edema. Protein S also enhances post-ischemic reperfusion and reduced brain fibrin and neutrophil deposition. Cortical neurons are protected from hypoxia / re-oxygenation-induced apoptosis. Thus, protein S and variants thereof are prototypes of a class of agents for preventing injury of the nervous system. In particular, a disease or other pathological condition (e.g., stroke) may be treated with such agents having one or more protein S activities (e.g., anti-thrombotic and anti-inflammatory activities, direct cellular neuronal protective effects) although the latter activities are not be required.

The present invention relates to a composition comprising factor VII or a factor VII-related polypeptide and a protein S inhibitor, and the use thereof for treating bleeding episodes.

A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

The invention discloses a novel recombinant coronavirus based on a vesicular stomatitis virus vector as well as a preparation method and application of the novel recombinant coronavirus. The novel recombinant coronavirus is a virus obtained by replacing glycoprotein G of vesicular stomatitis virus with envelope protein S; the envelope protein S comprises an envelope protein S extracellular region of 2019-nCoV (SAR-CoV-2) or a part of the sequence of the envelope protein S extracellular region. Experiments prove that the recombinant novel coronavirus can simulate the process that 2019-nCoV (SARS-CoV-2) invades cells, and can stimulate an organism to generate immunoreaction aiming at the 2019-nCoV (SARS-CoV-2), so that the recombinant novel coronavirus is an ideal tool for researching the infection process of the 2019-nCoV (SARS-CoV-2), can be developed into vaccines, and has a good application prospect. the recombinant novel coronavirus has important significance for screening inhibitors for inhibiting virus invasion and developing vaccines.

We describe a new technology for producing eggs containing recombinant proteins based on the novel use of avian adenoviruses (AAV). Adenovirus infected embryonated eggs are used as the host organism. The proteins synthesized are isolated in high amounts per egg and purified excluding time-consuming steps of purification. As far as is known, the mechanisms of translation and post-translational modification of proteins in avian species fully resembles those of other higher eukaryotes such as humans, veterinary animals, and plants. In contrast with bacterial, yeast and plant host system s for producing recombinant proteins, avian embryos allow isolation of protein s in biologically active form free of endotoxins. The combination of high productivity and possibility of obtaining proteins in native form makes the system a unique choice for biotechnology, much more favorable than other hosts currently being used for this purpose.

Methods are disclosed for determining, in a sample derived from a human, the functional activity of a component of the human blood coagulation system, which activity can be correlated to conversion of a substrate specific for activated Protein C (APC), by measuring in an assay medium containing the sample and a substrate for APC, the conversion of the substrate by APC and correlating the conversion to the functional activity of the component. When the component is anticoagulant Factor V, at least one of exogenous APC, Protein S or an inhibitor of Protein S activity is added to the medium. When the component is Protein C, APC, or Protein S, exogenous anticoagulant Factor V or an inhibitor of anticoagulant activity of Factor V is added to the medium. Methods are also disclosed for diagnosing a blood coagulation / anticoagulation disorder or for determining a predisposition thereto in a human by determining anticoagulant Factor V activity in an assay medium containing a sample derived from the human.

A nutritional or dietary egg supplement or food product is provided that may be eaten by children or adults. The food product is made solely of whole hen's eggs or egg whites that have been heat treated to selectively denature allergenic proteins s compared to a natural hen's egg.

Methods and assays for detecting S-sulfhydration of amino acids in proteins, polypeptides and peptides are provided. The method is a two-step “tag-switch” method employing two reagents consecutively to specifically label, with a detectable label, persulfide (—S—SH) linkages in proteins, polypeptides and peptides.

The use of vitamin K is provided in preparing pharmaceutical or nutraceutical products for counteracting an increased thrombosis risk caused by poor vitamin K status. The most likely mechanism underlying the vitamin K-insufficiency-induced thrombosis risk is undercarboxylation of vascular protein S. Preferably, vitamin K is a menaquinone, most preferably selected from the long-chain menaquinones MK-7 through MK-10.

The present invention relates to pro-coagulant human Protein S inhibitors, such as antibodies or antigen-binding fragments thereof that can be administered subcutaneously as prophylactic treatment for haemophilia patients regardless of inhibitor status and without interfering with non-coagulant functions of Protein S.

Methods for predicting an individual's genetic risk for developing venous thrombosis in diverse ethnic populations is disclosed, as are arrays and kits which can be used to practice the method. The method includes screening for mutations, polymorphisms, or both, in at least eight venous thrombosis-related molecules, such as antithrombin III, protein C, protein S, fibrinogen, factor V, prothrombin (factor II), methylenetetrahydrofolate reductase (MTHFR), and angiotensin I-converting enzyme (ACE) molecules which are associated with venous thrombosis.

A pharmaceutical agent for treating a disease such as inflammatory diseases, blood coagulation diseases associated with deficiency of Protein S has been required. The present invention provides a Protein S composition comprising recombinant Protein S molecules having complex type N-glycoside-linked sugar chains, wherein the Protein S has a higher binding activity to a receptor for advanced glycation end products (hereinafter referred to as “RAGE”) than native Protein S present in healthy human blood, and also has a higher ratio of sugar chains in which fucose is not bound to the complex type N-glycoside-linked sugar chains bound to Protein S than native Protein S present in healthy human blood.

The present invention relates generally to a method for modulating cell survival. Modulation of cell survival includes inducing, enhancing or otherwise promoting cell survival such as the survival of neural cells as well as facilitating cell death such as the death of targeted cancer cells. The modulation of cell survival is mediated by a region identified on the p75 neurotrophin receptor (p75NTR) required for death signalling. The present invention further provides genetic molecules which encode the death signalling region of p75NTR which are useful in antagonising death signal function as well as promoting cell death when expressed in targeted cells. The present invention also contemplates recombinant peptides, polypeptides and proteins s well as chemical equivalents, derivatives and homologues thereof which comprise the death signalling portion of p75NTR. Particularly useful molecules of the present invention comprise peptides corresponding to soluble forms of the death signalling portion of p75NTR. These molecules antagonise p75NTR-mediated cell death.

The invention provides a fusion protein for a novel coronavirus variant strain Delta, a nasal spray vaccine as well as a preparation method and application thereof, and belongs to the technical field of virus vaccines. The fusion protein for the novel coronavirus variant strain Delta is formed by fusing spike protein S, transmembrane protein M and nucleocapsid protein N; and coding genes of the protein S, the protein M and the protein N are sequentially shown as SEQ ID NO: 1-3. The nasal spray vaccine prepared by mixing the fusion protein and an adjuvant has good immunogenicity, safety and biological activity, and can induce an organism to generate an effective antibody, so that the growth of the novel coronavirus variant strain Delta is inhibited, and the Delta infection can be effectively prevented; by adopting the form of the nasal spray vaccine, injection is not needed, the operation is simple and convenient, and adverse reactions after use of an injection vaccine are avoided; and the preparation method of the vaccine is simple, and the vaccine is easy to purify and high in safety, and can be quickly applied to clinical tests.

The present invention relates to methods for detecting protein S-sulfinylation and S-sulfinylation within thiol groups in proteins, metabolites, or materials.

The invention discloses using secreted splicing variant of mammal Klotho (s-KL) as an agent for the prevention N and / or treatment of cognitive and / or behaviour impairments. It also refers to gene constructs and expression vectors useful in gene therapy for the delivery of said s-KL variant to the central nervous system of a mammal, in particular a rodent or a human. Pharmaceutical compositions comprising either the protein s-KL or any gene construct for expressing the protein in the CNS are also disclosed.

In one aspect, described herein is a method for monitoring cognitive decline in a subject, the method comprising (i) determining a level of one or more Dickkopf (Dkk) proteins in a blood sample from the subject; and (ii) comparing the level of the Dkk protein(s) to a reference value; wherein an increased level of the Dkk protein(s) in the sample compared to the reference value is indicative of increased cognitive decline in the subject.

The invention relates to the field of biological medicines and discloses application of protein S (Pros1) as a biological marker in preparation of a reagent for diagnosis of asthma and evaluation of the prognosis effect. The inventors find that the RNA level of Pros1 in peripheral blood of patients suffering from asthma is obviously higher than that of healthy people; further, the ELISA detectionis further performed on Pros1 in peripheral blood of patients suffering from mild and severe asthma and healthy people and finds that the protein level of Pros1 in peripheral blood of patients suffering from severe asthma is obviously higher than that of healthy people; and furthermore, for patients suffering from asthma, the protein level of Pros1 in peripheral blood of patients in the acute stage is higher than that of patients in the remission stage, so that the protein S can serve as the biological marker for diagnosis of asthma and evaluation of the prognosis effect.

The invention provides vectors containing a multiple cloning site comprising a PrS tag or a PrS2 tag from Myxococcus xanthus. Methods are provided for enhancing solubility of a target protein using Protein S tagged target fusion proteins.